Market Intelligence, Clinical Progress, and High-Purity Reagents for ISGylation Pathway Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for UBA7 (UBE1L) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | UBA7 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Sf9 Insect Cell expressed for optimal folding. |
View UBA7 Products |
| Gene Delivery | UBA7 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View UBA7 Products |
| Benchmark Ab | Anti-UBA7 Antibody Recombinant positive control for western blot, ELISA, and IP. |
View UBA7 Products |
| Validator | UBA7 siRNA Set For knockdown verification in functional assays. |
View UBA7 Products |
| Related Target A | ISG15 The primary ubiquitin-like modifier conjugated by UBA7. Essential for downstream ISGylation assays. |
View ISG15 Products |
| Related Target B | UBE2L6 (UBCH8) The E2 conjugating enzyme that acts downstream of UBA7 in the ISGylation cascade. |
View UBE2L6 Products |
| Related Target C | UBA1 The canonical Ubiquitin E1 enzyme. Crucial counter-screening target for selectivity profiling. |
View UBA1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity Counter-Screening (Off-target E1 enzymes) | Full panel of E1 enzymes (UBA1, UBA2, UBA3, UBA5, UBA7) available with >95% purity verified by SDS-PAGE. |
| Enzymatic Activity Reconstitution | Highly active, sequence-verified recombinant UBA7, ISG15, and UBE2L6 to support cell-free cascade assay development. |
| Lack of Controls | Validated reference antibodies and siRNA sets included for robust assay baselining. |
| False Positives in Small Molecule Screening | Endotoxin-controlled, high-purity proteins reduce non-specific interactions in assay readouts. |
Live UBA7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of UBA7 (also known as UBE1L), the primary E1 activating enzyme for the ISG15 conjugation pathway (ISGylation), is gaining significant momentum. Historically studied as a tumor suppressor in lung cancer, contemporary oncology and immunology research has revealed that the ISGylation pathway is frequently hijacked by tumors to promote immune evasion, chemotherapy resistance, and stemness. Consequently, the next wave of drug discovery is focusing on small-molecule inhibitors and PROTACs targeting UBA7 to disrupt aberrant ISGylation in solid tumors and interferonopathies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | Solid Tumors (Breast, Lung, Ovarian), Interferonopathies | High-throughput enzymatic assays (Requires active UBA7, ISG15, and UBE2L6 proteins) |
| PROTAC / Degraders | Targeted Protein Degradation (TPD) Developers | Autoimmune Diseases, Refractory Cancers | Ubiquitination/ISGylation profiling (Requires high-purity UBA7 for ternary complex assays) |
| Gene Therapy / RNAi | Preclinical Research Labs | Viral Infections, Inflammatory Disorders | Target validation and knockdown verification (Requires sequence-verified siRNA sets) |